doctor supervised weight loss
Doctor supervised weight loss with GLP-1 therapy in Hong Kong
Scientific Body Shaping
Weight Management — Scientific Body Shaping, Doctor-Supervised
Achieve sustainable weight loss backed by science, not fad diets. Physician-led GLP-1 and GLP-1/GIP therapy, with ongoing clinical monitoring.
GLP-1 and GLP-1/GIP therapies are prescription medications. A doctor consultation and full medical assessment are required before any prescription is issued. This information does not constitute medical advice.
Licensed Doctors Only
Prescription Required — No Self-Purchase
Confidential Consultation
Genuine, HK-Registered Medication
Doctor supervised weight loss with GLP-1 therapy in Hong Kong
Doctor supervised weight loss with GLP-1 therapy in Hong Kong
The Obesity Landscape in Hong Kong
Weight management has become a critical health issue in Hong Kong's fast-paced urban environment. Local health data shows approximately 32.6% of adults aged 15–84 meet the clinical threshold for obesity (BMI ≥25), with a further 22% classified as overweight (BMI ≥23–24.9). Nearly 40% of overweight individuals do not accurately recognise their own weight status — underscoring the importance of proper medical assessment over guesswork.
Excess weight is not merely a cosmetic concern. It is a recognised driver of type 2 diabetes, cardiovascular disease, hypertension, obstructive sleep apnea, and certain cancers. Medical weight management addresses both the weight and the underlying metabolic risk.
How It Works
Online enquiry or consultation booking
In-clinic doctor assessment — BMI, medical history, contraindication screening
Personalised prescription — Semaglutide or Tirzepatide, based on your health profile
Ongoing treatment — regular doctor follow-up and clinical monitoring throughout
doctor supervised weight loss
Treatment Options
Wegovy® (Semaglutide)
- Mechanism: GLP-1 receptor agonist — suppresses appetite, increases satiety, slows gastric emptying
- Frequency: Once weekly injection
- Best For: Sustained long-term weight control
- Clinical Backing: Large-scale STEP trial programme
Mounjaro® (Tirzepatide)
- Mechanism: Dual GLP-1/GIP receptor agonist — appetite control + enhanced metabolic and fat-storage effect
- Frequency: Once weekly injection
- Best For: Higher-intensity cases; also supports blood sugar control in type 2 diabetes
- Clinical Backing: SURMOUNT trial programme — greater average weight reduction vs. GLP-1 alone
Lifestyle & Nutrition Coaching Add-On — Behavioural and lifestyle support to complement your prescription treatment — for long-term maintenance and habit formation. Available as an ongoing add-on to either treatment pathway.
Why Mounjaro® (Tirzepatide) May Be Right for You
Tirzepatide is the first dual-receptor agonist targeting both GLP-1 and GIP pathways simultaneously.
- Stronger blood sugar regulation through complementary insulin-secretion pathways
- More significant weight reduction in clinical studies compared to GLP-1-only agents
- Additional metabolic health benefits, including reduced cardiovascular risk factors
- Suitable for patients with type 2 diabetes seeking both glycaemic control and weight loss
Your doctor will determine which treatment is most appropriate for your individual health profile during consultation.
Who May Be Suitable for This Treatment
- Adults with a BMI of 30 kg/m² or higher
- Adults with a BMI of 27–29.9 kg/m² with weight-related conditions (e.g., high blood pressure, abnormal cholesterol, prediabetes, type 2 diabetes, sleep apnea)
- Adults with type 2 diabetes seeking better glycaemic control alongside weight management
Eligibility is determined by a doctor during your in-clinic consultation. Not all patients will be suitable.
Important Safety Information
GLP-1 and GLP-1/GIP therapies are prescription medications and must be used under a doctor's supervision. Patients must complete an in-clinic consultation, medical history review, and contraindication screening before any medication is prescribed or dispensed.
These treatments are not suitable for patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pancreatitis, or who are pregnant or breastfeeding.
This information does not constitute medical advice and cannot replace a healthcare professional's clinical judgement.
FAQs
What's the difference between Semaglutide (Wegovy®) and Tirzepatide (Mounjaro®)?
Semaglutide targets the GLP-1 pathway alone, while Tirzepatide targets both GLP-1 and GIP pathways simultaneously, which may offer enhanced appetite control and metabolic benefit for some patients. Your doctor will help determine which is more suitable for your individual health profile.
Is this treatment safe?
When prescribed and monitored by a licensed doctor, both therapies have well-established safety profiles supported by large-scale clinical trials. Common side effects include mild nausea and reduced appetite, which typically decrease over time.
How quickly will I see results?
Most patients begin to notice appetite changes within the first few weeks. Meaningful weight loss typically becomes evident within 4–8 weeks, with continued progress over 3–6 months of treatment.
Do I need to follow a diet while on treatment?
The medication works best when combined with a balanced diet and regular physical activity. Our team provides guidance on lifestyle modifications to maximise and sustain your results.
Who should NOT use this treatment?
Patients with certain thyroid conditions, pancreatitis history, or who are pregnant or breastfeeding should not use GLP-1/GIP therapy. A full medical history review during consultation determines eligibility.